| Xylazine hydrochloride |
![]() Last updated: 06/09/2025 |
![]() |
(Also known as: xylene HCl; BAY 1470 hydrochloride; xylazine chloride ) |
|
|
|
A thiazine derivative used in veterinary medicine for sedation | |
|---|---|---|
|
Used to produce sedation and short periods of analgesia | |
|
Horses; Cattle; Elephants; Deer; Cats; Dogs; Sheep; Goats; Hedgehogs; Other farm and zoo animals |
| Approval status |
|
Approved - usually available as a tprescription-only-medicine to be authorised by a veterinarian (POM-V) | |
|---|---|---|
|
Approved |
| Chemical structure |
|
None | |
|---|---|---|
|
C₁₂H₁₇ClN₂S | |
|
c1(C)c(NC=2SCCCN2)c(ccc1)C.Cl | |
|
- | |
|
QYEFBJRXKKSABU-UHFFFAOYSA-N | |
|
InChI=1S/C12H16N2S.ClH/c1-9-5-3-6-10(2)11(9)14-12-13-7-4-8-15-12;/h3,5-6H,4,7-8H2,1-2H3,(H,13,14);1H | |
|
Yes |
|
|
| Common Name | Relationship | Link |
|---|---|---|
| xylazine hydrochloride monohydrate | Hydrate | ![]() |
| General status |
|
Sedative, Anesthestic, Analgesis, Muscle relaxant, Medicinal drug | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Clonidine analoque | ||||||||||||||
|
>99% | ||||||||||||||
|
- | ||||||||||||||
|
Synthetic | ||||||||||||||
|
Stimulates central α2-receptors. α2-adrenergic which decreases the release of norepinephrine and dopamine in the central nervous system causing the sedation | ||||||||||||||
|
[Alpha-2-adrenergic, Agonist] | ||||||||||||||
|
23076-35-9 | ||||||||||||||
|
245-417-0 | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Nervous system: Psycholeptics | ||||||||||||||
|
QN05CM92 | ||||||||||||||
|
No | ||||||||||||||
|
Allowed substance (Table 1: Bovine, Equidae) | ||||||||||||||
|
256.79 | ||||||||||||||
|
- | ||||||||||||||
|
2-(2,6-xylidino)-5,6-dihydro-4H-1,3-thiazine hydrochloride | ||||||||||||||
|
N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazine-2-amine hydrochloride | ||||||||||||||
|
|
||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
White crystalline solid | ||||||||||||||
|
|||||||||||||||
| Commercial |
|
|
|||
|---|---|---|---|---|
|
Current | |||
|
1962, first synthesised | |||
|
|
|||
|
|
|||
|
Usually supplied in solution for injection or as a powder to be prepared as a solution | |||
|
Xylazine hydrochloride is synthesised through a multi-step chemical process beginning with 2,6-dimethylaniline, which undergoes acetylation using acetic anhydride in a solvent like tetrahydrofuran to form an intermediate amide. This intermediate is then cyclised and modified to introduce the thiazine ring, a key structural feature of xylazine. The resulting compound is further reacted with hydrochloric acid to form the hydrochloride salt, enhancing its solubility and stability for pharmaceutical use. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
|
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
164 | E3 E = Manufacturers safety data sheets 3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
| Degradation |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- | ||||||||||
| Soil adsorption and mobility |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
| Fate indices |
|
|
|
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - | |||||||||||||||||||||||||||
| Known soil and groundwater metabolites |
None
| Other known metabolites |
|
|
|
|
||||
|---|---|---|---|---|---|---|---|
| 1-amino-2,6-dimethylbenzene | 2,6-xylidine | Cattle (Urine) | - | ||||
| 2-(4'-hydroxy-2',6'-di-methylphenylamino)-5,6-dihydro-4H-1,3-thiazine | - | Horses; Rats (liver) | - | ||||
| 2-(3'-hydroxy-2',6'-dimethylphenylamino)-5,6-dihydro-4H-1,3-thiazine | - | Horses; Rats (liver) | - | ||||
| N-(2,6-dimethylphenyl)thiourea | - | Horses; Rats (liver) | - | ||||
| 2-(2',6'-dimethylphenylamino)-4-oxo-5,6-dihydro-1,3-thiazine | - | Horses; Rats (liver) | - |
|
|
| Terrestrial ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
> 109 | E3 E = Manufacturers safety data sheets Mouse3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
| - | |||||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- |
|
- | - | - | ||||||
|
- | ||||||||||
| Aquatic ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
> 18.0 | E3 E = Manufacturers safety data sheets Daphnia magna3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - | ||||||||
|
|
| General |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
High (class III) | - | - | ||||||||
|
> 109 | E3 E = Manufacturers safety data sheets Mouse3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
Subcutaneous TDLo = 0.029 mL kg⁻¹ | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) Mouse3 = Unverified data of known source |
- | ||||||||
| Intramuscular TDLo = 109 mg kg⁻¹ | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) Mouse3 = Unverified data of known source |
- | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Extensive metabolism occurs with <1% unchanged being eliminated via urine in the first two hours after administration | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- | ||||||||
| Health issues |
|
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Possible liver toxicant Adverse effects of xylazine in animals include muscle tremors, seizures and slowed heart rate May cause vomiting |
||||||||||||||||||||||||||||
| Handling issues |
|
|
|||
|---|---|---|---|---|
|
No information available | |||
|
- | |||
|
Not listed (Not listed) | |||
|
- | |||
|
- | |||
|
- |
|
|
|
|
||
|---|---|---|---|
|
xylazine hydrochloride | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
| Record last updated: | 06/09/2025 |
| Contact: | aeru@herts.ac.uk |
| Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |
© Copyright University of Hertfordshire, 2006-2026. All Rights Reserved
Your use of this website and its various databases is subject to the terms detailed in the University of Hertfordshire’s copyright and IPR statement that can be found at https://www.herts.ac.uk/about-us/legal. In addition, your use of this website and its various databases is subject to the terms of this additional Copyright Statement and the database Conditions of use document. Unless explicitly stated otherwise, the content of this website and databases are owned and controlled by the University of Hertfordshire. Site content, including its selection and arrangement, is owned by the University of Hertfordshire and is protected by copyright and other laws. Except as otherwise expressly permitted under copyright law or within the database Conditions of Use document, the content of this site may not be copied, reproduced, republished, downloaded, posted, broadcast or transmitted in any way without first obtaining the University of Hertfordshire’s written permission. By using our databases the user is deemed to have agreed to comply with all of the terms and conditions as described above and within all relevant documentation.





